glp-1 news oct 21 2025 obesity drug Weight Loss Enforcement in 2025: State Attorneys General Step into a Growing Regulatory Gap GLP-1 Weight-Loss Drug Alarming rise in weight loss

nuclear factor erythroid-2-related factor, Nrf2

Our aim was to determine the effects of GLP-1R agonism on the liver in mouse models of high ethanol consumption

Absence of growth retardation in children with perennial allergic rhinitis after one year of treatment with mometasone furoate aqueous nasal spray

Thats especially true with weekly GLP1 injections, where timing affects how the medication builds up and tapers off throughout the week

Incidence, risk factors and evaluation of osteoporosis in patients with inflammatory bowel disease: a Danish population-based inception cohort with 10 years of follow-up

= from 0.026 to 0.028 for each CFS subgroup)